---
title: "Helus’ HLP003 reduced depression scores in Phase 3 but safety questions remain"
id: "stat-news-4-stat-helus-psychedelic-drug-improved-depression-in-study-but-faces-safety"
canonical_url: "https://medichelpline.com/clinical-feed/stat-news-4-stat-helus-psychedelic-drug-improved-depression-in-study-but-faces-safety"
content_type: "clinical_feed_article"
specialty: "Pharmacology"
source_name: "STAT News"
source_url: "https://www.statnews.com/2026/11/16/helus-psychedelics-depression-phase-3-trial/?utm_campaign=rss"
published_at: "2026-11-16T13:07:47.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Helus’ HLP003 reduced depression scores in Phase 3 but safety questions remain
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/stat-news-4-stat-helus-psychedelic-drug-improved-depression-in-study-but-faces-safety
- **Specialty:** [Pharmacology](https://medichelpline.com/clinical-feed/pharmacology.md)
- **Primary Source:** STAT News
- **Source URL:** [Original Journal Publication](https://www.statnews.com/2026/11/16/helus-psychedelics-depression-phase-3-trial/?utm_campaign=rss)
- **Published At:** 2026-11-16T13:07:47.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- Helus reported Phase 3 results for its psychedelic candidate **HLP003** showing larger reductions in depressive symptoms versus placebo on the **MADRS** scale at both six and 12 weeks. - Patients received one dose on day 1 and a second dose three weeks later; the company reported outcomes at six and 12 weeks. - At six weeks the treatment arm had a 19.5-point mean drop on the **MADRS**, versus an 11.9-point drop in the placebo arm — a between-group difference the company described as statistically significant. - At 12 weeks the treatment group showed a 16.9-point reduction and the placebo group a 9.9-point reduction; these differences were also reported as statistically significant. - The trial enrolled participants who remained on their standard antidepressant regimens while receiving the study drug; the source did not provide details on inclusion/exclusion criteria or concomitant medication specifics. - Investigators observed a number of serious adverse events during the study; the public report did not disclose counts, specific event types, or severity grading. - The company presented efficacy and safety together; data indicated maintained effect at 12 weeks but raised unresolved safety questions that the source emphasized. - The source did not report additional methodology items such as randomization ratio, sample size, country sites, blinding procedures, or statistical analysis plan details. - Regulatory pathway steps or planned submissions were not described in the article; the report focused on topline efficacy and noted unresolved safety signals. - The study team observed short-term symptom improvement, but the incomplete safety detail leaves unanswered clinical questions about tolerability and risk/benefit balance.
## Clinical Analysis & Structured Key Points
[Skip to Main Content](https://www.statnews.com/2026/11/16/helus-psychedelics-depression-phase-3-trial/?utm_campaign=rss#wrapper) [ ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo-white.svg) ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo.svg) ](https://www.statnews.com/) * [Manage alerts for this article](https://www.statnews.com/my-account/edit/#emails) * [Save this story for later](https://www.statnews.com/my-account/saved/) * [Share this article](https://www.statnews.com/2026/11/16/helus-psychedelics-depression-phase-3-trial/?utm_campaign=rss) [Clinical trials](https://www.statnews.com/topic/clinical-trials/) [Cancer](https://www.statnews.com/topic/cancer/) [patients](https://www.statnews.com/topic/patients/) * [Newsletters](https://www.statnews.com/signup/) * [Log In](https://www.statnews.com/login/) * [My Account](https://www.statnews.com/my-account/) * [Subscribe Now](https://www.statnews.com/stat-plus/) My Account * [Settings Complete your personal information for a more tailored experience ](https://www.statnews.com/my-account/) * [Saved Stories](https://www.statnews.com/my-account/saved/) * [Billing](https://www.statnews.com/my-account/billing/) * [Log In](https://www.statnews.com/login/) [ ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo.svg) Reporting from the frontiers of health and medicine ](https://www.statnews.com/) * [Newsletters](https://www.statnews.com/signup/) * [Log In](https://www.statnews.com/login/) * [My Account](https://www.statnews.com/my-account/) * [Subscribe Now](https://www.statnews.com/stat-plus/) * [Biotech](https://www.statnews.com/category/biotech/) * [Pharma](https://www.statnews.com/category/pharma/) * [Public Health](https://www.statnews.com/category/health/) * [Health Tech](https://www.statnews.com/category/health-tech/) * [Policy](https://www.statnews.com/category/politics/) * [Science](https://www.statnews.com/category/in-the-lab/) * [First Opinion](https://www.statnews.com/category/first-opinion/) * [STAT+](https://www.statnews.com/topic/stat-plus/) * [Midterms 2026](https://www.statnews.com/midterms-2026-health-care-policy-issues/) [ ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo.svg) ](https://www.statnews.com/) Search * [Log In](https://www.statnews.com/login/) * [Subscribe Now](https://www.statnews.com/stat-plus/) * [My Account](https://www.statnews.com/my-account/) My Account * [Settings](https://www.statnews.com/my-account/) * [Saved Stories](https://www.statnews.com/my-account/saved/) * [Billing History](https://www.statnews.com/my-account/billing/) [Home](https://www.statnews.com/) News * [Latest](https://www.statnews.com/latest/) * [Series & Investigations](https://www.statnews.com/stat-series-and-investigations-award-winning-journalism/) * Business * [Biotech](https://www.statnews.com/category/biotech/) * [Pharma](https://www.statnews.com/category/pharma/) * [Health Tech](https://www.statnews.com/category/health-tech/) * [Health Insurance](https://www.statnews.com/category/insurance/) * [Hospitals](https://www.statnews.com/category/hospitals/) * [Medical Devices](https://www.statnews.com/topic/medical-devices/) * Washington * [Policy](https://www.statnews.com/category/politics/) * [FDA](https://www.statnews.com/topic/fda/) * [NIH](https://www.statnews.com/topic/nih/) * Science * [CRISPR](https://www.statnews.com/topic/crispr/) * [Gene Therapy](https://www.statnews.com/topic/gene-therapy/) * [Neuroscience](https://www.statnews.com/topic/neuroscience/) * Public Health * [Addiction](https://www.statnews.com/topic/addiction/) * [Covid-19](https://www.statnews.com/topic/coronavirus/) * [Abortion](https://www.statnews.com/topic/abortion/) * [Health Disparities](https://www.statnews.com/topic/health-disparities/) * [Infectious Disease](https://www.statnews.com/topic/infectious-disease/) * [Mental Health](https://www.statnews.com/topic/mental-health/) * Disease * [Cancer](https://www.statnews.com/topic/cancer/) * [Cardiovascular Disease](https://www.statnews.com/topic/cardiovascular-disease/) * [Chronic Disease](https://www.statnews.com/topic/chronic-disease/) * [Diabetes](https://www.statnews.com/topic/diabetes/) * [Alzheimer's](https://www.statnews.com/topic/alzheimers/) * [Obesity](https://www.statnews.com/topic/obesity/) * Features * [Trust in Science](https://www.statnews.com/trust-in-science/) * [Health Care Costs](https://www.statnews.com/health-insurance-costs-out-of-pocket-out-of-reach-series/) * [The Deadliest Drug](https://www.statnews.com/alcohol-epidemic-hiding-plain-sight-deadliest-drug-series/) [Newsletters](https://www.statnews.com/signup/) [Opinion](https://www.statnews.com/category/first-opinion/) Columns * [Adam Feuerstein](https://www.statnews.com/category/adams-take/) * [Matthew Herper](https://www.statnews.com/category/matts-take/) * [Ed Silverman](https://www.statnews.com/category/pharmalot-view/) [Reports](https://reports.statnews.com/) [E-books](https://www.statnews.com/ebooks/) [Podcasts](https://www.statnews.com/podcasts/) [Tools & Trackers](https://www.statnews.com/trackers/) * [CRISPR Tracker](https://www.statnews.com/feature/crispr/tracker/) * [Breakthrough Device Tracker](https://www.statnews.com/feature/stat-plus/breakthrough-device-designation-fda-tracker/) * [Generative AI Tracker](https://www.statnews.com/feature/stat-plus/generative-ai-health-hospitals-tracker/) * [Obesity Drug Tracker](https://www.statnews.com/2023/09/12/new-weight-loss-drug-tracker-novo-nordisk-eli-lilly/) [Events](https://www.statnews.com/events/) * [Upcoming Events](https://www.statnews.com/events#upcoming-events) * [Summits](https://www.statnews.com/stat-summits/) [Community](https://www.statnews.com/community/) * [STAT Madness 2027](https://www.statnews.com/feature/stat-madness/apply/) [Video](https://youtube.com/@Statnews) [Advertise](https://www.statnews.com/advertise/) * [STAT Brand Studio](https://sbs.statnews.com/) What's the word? Test your knowledge with our new weekday mini crossword [ Start solving ](https://www.statnews.com/stat-mini-crossword/) [STAT Plus](https://www.statnews.com/stat-plus/)[Biotech](https://www.statnews.com/category/biotech/) # Helus’ psychedelic drug improved depression in study but faces safety questions ## Helus is one of a number of companies pursuing psychedelics for depression * [Manage alerts for this article](https://www.statnews.com/my-account/edit/#emails) * [Save this story for later](https://www.statnews.com/my-account/saved/) * [Share this article](https://www.statnews.com/2026/11/16/helus-psychedelics-depression-phase-3-trial/?utm_campaign=rss) ![Stock exchange](https://www.statnews.com/wp-content/uploads/2021/12/GettyImages-1076619156-645x645.jpg) Drew Angerer/Getty Images ![](https://www.statnews.com/wp-content/uploads/2022/12/elaine-chen-avatar-round-80x80.png) By [Elaine Chen](https://www.statnews.com/staff/elaine-chen/) Nov. 16, 2026 National Biotech Reporter ![](https://www.statnews.com/wp-content/uploads/2022/12/elaine-chen-avatar-round-80x80.png) [Elaine Chen](https://www.statnews.com/staff/elaine-chen/) 1. [](https://www.linkedin.com/in/elaineywchen/ "Linkedin") 2. [](https://x.com/elaineywchen "X") elaine.chen@statnews.com Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes [The Readout newsletter](https://www.statnews.com/signup/readout/), and co-hosts STAT’s weekly biotech podcast, [The Readout Loud](https://www.statnews.com/category/readout-loud/). You can reach Elaine on Signal at elaineywchen.70. A psychedelic drug candidate from Helus Pharma significantly helped people with major depression in a Phase 3 trial, the company said Monday, but a number of serious adverse events in the study raised questions about the safety of the treatment. Participants took one dose of the drug, called HLP003, on the first day of the trial and a second dose three weeks later. Six weeks into the study, people taking the drug in addition to their standard antidepressants experienced a reduction of 19.5 points on a depression rating scale called the MADRS, while the placebo group had a 11.9-point reduction. Advertisement At 12 weeks, the effect was largely maintained, with the treatment group seeing a 16.9-point reduction and the placebo group experiencing a 9.9-point reduction. The differences between the two groups were all statistically significant. [![STAT+](https://www.statnews.com/wp-content/themes/stat/images/stat-plus-logo.svg)](https://www.statnews.com/stat-plus/) To read the rest of this story subscribe to STAT+. [Subscribe](https://www.statnews.com/stat-plus/) [Log In](https://www.statnews.com/login/) [drug development](https://www.statnews.com/topic/drug-development/), [Mental Health](https://www.statnews.com/topic/mental-health/), [Pharmaceuticals](https://www.statnews.com/topic/pharmaceuticals/), [STAT+](https://www.statnews.com/topic/stat-plus/) [Submit a correction request](https://www.statnews.com/contact/?how_can_we_help_=Editorial%20Correction%20Request)[Reprints](https://www.parsintl.com/publications/stat/) 1. ![](https://www.statnews.com/wp-content/uploads/2022/12/elaine-chen-avatar-round-80x80.png) [Elaine Chen](https://www.statnews.com/staff/elaine-chen/) 1. [](https://x.com/elaineywchen "X") 2. [](https://bsky.app/profile/elaineywchen.bsky.social "Bluesky") 3. 4. [](https://www.linkedin.com/in/elaineywchen/ "Linkedin") National Biotech Reporter 1. [](https://x.com/elaineywchen "X") 2. [](https://bsky.app/profile/elaineywchen.bsky.social "Bluesky") 3. 4. [](https://www.linkedin.com/in/elaineywchen/ "Linkedin") Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes [The Readout newsletter](https://www.statnews.com/signup/readout/), and co-hosts STAT’s weekly biotech podcast, [The Readout Loud](https://www.statnews.com/category/readout-loud/). You can reach Elaine on Signal at elaineywchen.70. ![](https://www.statnews.com/wp-content/themes/stat/images/article-new/envelope-open.svg) ![](https://www.statnews.com/wp-content/uploads/2023/06/Morning-Rounds-Logo-Black-640x295.png) ### Newsletter Understand how science, health policy, and medicine shape the world every day Please enter a valid email address. Sign Up Your data will be processed in accordance with our [Privacy Policy](https://www.statnews.com/privacy/) and [Terms of Service](https://www.statnews.com/terms-conditions/). You may opt out of receiving STAT communications at any time. Advertisement Most Popular 1. ![](https://www.statnews.com/wp-content/uploads/2024/09/GettyImages-1237273640-1-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [FDA rejects lung cancer treatment ivonescimab from Summit Therapeutics](https://www.statnews.com/2026/11/15/fda-rejects-ivonescimab-lung-cancer-treatment-summit-therapeutics/) 2. ![](https://www.statnews.com/wp-content/uploads/2026/11/AdobeStock_2158931352-80x80.jpeg) [Medical school should start after students take the Step 1 exam](https://www.statnews.com/2026/11/16/medical-school-step-1-exam-redesign-proposal/) 3. ![](https://www.statnews.com/wp-content/uploads/2026/08/AdobeStock_180917809-80x80.jpeg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Bladder cancer immunotherapy from CG Oncology reduced risk of tumor recurrence](https://www.statnews.com/2026/11/16/bladder-cancer-immunotherapy-reduced-tumor-recurrence-cg-oncology/) 4. ![](https://www.statnews.com/wp-content/uploads/2026/11/AdobeStock_331634765-80x80.jpeg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Versant, Lilly put $100 million behind new startup aimed at solving one of gene therapy’s thorniest issues](https://www.statnews.com/2026/11/16/versant-lilly-put-100-million-behind-new-startup-aimed-at-solving-one-of-gene-therapys-thorniest-issues/) 5. ![](https://www.statnews.com/wp-content/uploads/2026/11/GettyImages-2298594379-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [With Stephen Miller as chief of staff, Kennedy’s MAHA agenda is reinvigorated](https://www.statnews.com/2026/11/16/stephen-miller-chief-of-staff-boosts-power-of-kennedy-maha/) #### [ Reports ](https://reports.statnews.com/) [ ![](https://www.statnews.com/wp-content/uploads/2026/08/2026_CancerReport_ReportCover-328x424.jpg) Explore Cancer’s transformational moments: KRAS, CAR-T, immunotherapy, and more ](https://reports.statnews.com/products/cancer-transformational-moments-advances-in-kras-car-t-immunotherapy) Advertisement #### [Events](https://www.statnews.com/events/) [ ![](https://www.statnews.com/wp-content/uploads/2026/10/STATatHLTH_Wordpress_CalendarImage-80x80.jpg) STAT@hlth. A Dose of Reality on EHRs and AI In-person Nov 18 ](https://www.statnews.com/event/stathlth-a-dose-of-reality-on-ehrs-and-ai/) [ ![](https://www.statnews.com/wp-content/uploads/2026/09/2026ASH_Wordpress_CalendarImage-80x80.jpg) STAT@ASH: Medicine’s Bleeding Edge New Orleans, LA Dec 13 ](https://www.statnews.com/event/stat-at-ash-meeting-2026/) [ ![](https://www.statnews.com/wp-content/uploads/2026/09/BTE2027_Wordpress_CalendarImage-80x80.jpg) 2027 Breakthrough Summit East New York City, NY Mar 18 ](https://www.statnews.com/event/2027-stat-breakthrough-summit-east/) Most Read in [STAT+](https://www.statnews.com/stat-plus/) 1. ![](https://www.statnews.com/wp-content/uploads/2026/11/AdobeStock_6400491-80x80.jpeg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [FDA warns GLP-1 drugs carry potential risk of rare eye condition](https://www.statnews.com/2026/11/09/glp-1-drugs-potential-risk-rare-eye-condition-naion-fda/) 2. ![](https://www.statnews.com/wp-content/uploads/2026/10/AdobeStock_391451620_Editorial_Use_Only-80x80.jpeg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Former Eli Lilly rep claims she was fired for complaining about marketing of Mounjaro diabetes drug](https://www.statnews.com/pharmalot/2026/11/10/former-lilly-rep-claims-she-was-fired-for-complaining-about-marketing-of-mounjaro-diabetes-drug/) 3. ![](https://www.statnews.com/wp-content/uploads/2019/09/AP_060324030695-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [FDA approves novel Bayer drug to reduce recurrence of stroke](https://www.statnews.com/2026/11/09/cardiovascular-stroke-recurrence-bayer-drug-fda-approval/) 4. ![](https://www.statnews.com/wp-content/uploads/2024/09/GettyImages-1237273640-1-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [FDA rejects lung cancer treatment ivonescimab from Summit Therapeutics](https://www.statnews.com/2026/11/15/fda-rejects-ivonescimab-lung-cancer-treatment-summit-therapeutics/) 5. ![](https://www.statnews.com/wp-content/uploads/2026/05/AP26023803702193-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Oura’s acquisition of health tech startup raises conflict-of-interest questions for Eli Lilly, experts say](https://www.statnews.com/2026/11/13/oura-acquisition-counsel-health-eli-lilly/) #### Recommended ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) Biotech Biotech November 16, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: Bladder cancer immunotherapy from CG Oncology reduced risk of tumor recurrence ](https://www.statnews.com/2026/11/16/bladder-cancer-immunotherapy-reduced-tumor-recurrence-cg-oncology/) By [Adam Feuerstein](https://www.statnews.com/staff/adam-feuerstein/) ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) Biotech Biotech November 16, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: Versant, Lilly put $100 million behind new startup aimed at solving one of gene therapy’s thorniest issues ](https://www.statnews.com/2026/11/16/versant-lilly-put-100-million-behind-new-startup-aimed-at-solving-one-of-gene-therapys-thorniest-issues/) By [Jason Mast](https://www.statnews.com/staff/jason-mast/) Advertisement ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) Biotech Biotech November 16, 2026 ### [ China’s Biotech Powerhouse 25, a STAT-WireScreen ranking of top companies ](https://www.statnews.com/china-biotech-index-powerhouse-25) By STAT Staff ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) Biotech Biotech November 16, 2026 ### [ BeOne, Hengrui top list of China’s most powerful drugmakers ](https://www.statnews.com/2026/11/16/beone-hengrui-top-list-of-chinas-most-powerful-drugmakers/) By [Damian Garde](https://www.statnews.com/staff/damian-garde/) ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) Biotech Biotech November 15, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: FDA rejects lung cancer treatment ivonescimab from Summit Therapeutics ](https://www.statnews.com/2026/11/15/fda-rejects-ivonescimab-lung-cancer-treatment-summit-therapeutics/) By [Adam Feuerstein](https://www.statnews.com/staff/adam-feuerstein/) #### Subscriber Picks 1. ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: CVS’ split doesn’t fix its fundamental problem ](https://www.statnews.com/2026/11/09/cvs-health-split-pbm-conflict-examined-anthony-loiacono-judi-health/) By A.J. Loiacono 2. ### [ A new tactic in the war over out-of-network bills: Health care providers are suing employers ](https://www.statnews.com/2026/11/11/no-surprises-act-phi-health-air-ambulance-sues-employers/) By [Bob Herman](https://www.statnews.com/staff/bob-herman/) 3. ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: Failure of Novartis Lp(a) drug raises questions about cardiovascular strategy ](https://www.statnews.com/2026/11/07/aha-conference-news-novartis-lp-a-pelacarsen-heart-disease-trial-mystery/) By [Elizabeth Cooney](https://www.statnews.com/staff/elizabeth-cooney/) and [Matthew Herper](https://www.statnews.com/staff/matthew-herper/) 4. ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: Former Eli Lilly rep claims she was fired for complaining about marketing of Mounjaro diabetes drug ](https://www.statnews.com/pharmalot/2026/11/10/former-lilly-rep-claims-she-was-fired-for-complaining-about-marketing-of-mounjaro-diabetes-drug/) By [Ed Silverman](https://www.statnews.com/staff/ed-silverman/) 5. ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: FDA warns GLP-1 drugs carry potential risk of rare eye condition ](https://www.statnews.com/2026/11/09/glp-1-drugs-potential-risk-rare-eye-condition-naion-fda/) By [Elaine Chen](https://www.statnews.com/staff/elaine-chen/) Share options * [ X ](https://twitter.com/intent/tweet?url=https://www.statnews.com/2026/11/16/helus-psychedelics-depression-phase-3-trial/&via=statnews&text=Helus%E2%80%99%20psychedelic%20drug%20improved%20depression%20in%20study%20but%20faces%20safety%20questions "Share on X") * [ Bluesky ](https://bsky.app/intent/compose?text=Helus%E2%80%99%20psychedelic%20drug%20improved%20depression%20in%20study%20bu
## Related Clinical Research

- [FDA proposes new supplement category for N-acetyl-L-cysteine (NAC)](https://medichelpline.com/clinical-feed/stat-news-3-stat-in-a-win-for-maha-fda-creates-new-regulatory-category-for-the-supplement.md)
- [Exercise Prescriptions for Concussion Recovery: An Urgent Call to Action](https://medichelpline.com/clinical-feed/stat-news-2-opinion-more-doctors-should-prescribe-exercise-after-a-concussion.md)
- [Reduced added sugar in the first 1,000 days tied to lower Alzheimer’s and dementia risk](https://medichelpline.com/clinical-feed/medical-news-today-0-cutting-added-sugar-before-age-2-linked-to-lower-dementia-depression-risk-in.md)
- [U.S. POINTER: Structured lifestyle program slows brain aging and cardiometabolic risk over 24 mont](https://medichelpline.com/clinical-feed/medical-news-today-0-combining-physical-mental-and-social-habits-slows-brain-aging-in-2-year-trial.md)
- [Understanding Heart Health at Every Life Stage for Women](https://medichelpline.com/clinical-feed/aha-news-1-why-every-stage-of-life-matters-for-a-woman-s-heart-health.md)

## Navigation
- [← Back to Pharmacology Feed](https://medichelpline.com/clinical-feed/pharmacology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.